P11274
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
bcr
NCBI Official Synonym Full Names
breakpoint cluster region
NCBI Official Synonym Symbols
ALL; CML; PHL; BCR1; D22S11; D22S662; FLJ16453 [Similar Products]
NCBI Protein Information
breakpoint cluster region protein; OTTHUMP00000028949; OTTHUMP00000067895; renal carcinoma antigen NY-REN-26
UniProt Protein Name
Breakpoint cluster region protein
UniProt Synonym Protein Names
Renal carcinoma antigen NY-REN-26
UniProt Synonym Gene Names
UniProt Entry Name
BCR_HUMAN
NCBI Summary for BCR
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq]
UniProt Comments for BCR
Bcr: a protein with serine/threonine protein kinase activity and is a GTPase-activating protein (GAP) for RAC1 and CDC42. The amino-terminal region of Bcr contains an oligomerization domain, a serine/threonine kinase domain and a region that binds SH2 domains. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The carboxy-terminal region promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. A breakpoint cluster region protein that participates in a t(9;22)(q34;q11) chromosomal translocation that produces a BCR-ABL oncogene responsible for chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The function of wild type Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstream signaling mediator. Tyr177 of human Bcr, phosphorylated in the Bcr-Abl fusion protein, provides a docking site for Gab2 and GRB2, and is important in the transforming activity of Bcr-Abl. Sequence variants of the Bcr protein may be associated with bipolar disorder. Two alternatively spliced isoforms of the human protein have been reported.
Protein type: Kinase, protein; GAPs; GEFs, Rac/Rho; Protein kinase, atypical; EC 2.7.11.1; Protein kinase, Ser/Thr (non-receptor); Oncoprotein; GAPs, Rac/Rho; ATYPICAL group; BCR family
Chromosomal Location of Human Ortholog: 22q11.23
Cellular Component: postsynaptic membrane; protein complex; membrane; postsynaptic density; cell junction; cytosol
Molecular Function: protein serine/threonine kinase activity; protein binding; Rho guanyl-nucleotide exchange factor activity; enzyme binding; protein-tyrosine kinase activity; kinase activity; GTPase activator activity; ATP binding
Biological Process: inner ear morphogenesis; peptidyl-tyrosine phosphorylation; regulation of cell cycle; protein amino acid autophosphorylation; platelet-derived growth factor receptor signaling pathway; response to lipopolysaccharide; signal transduction; protein amino acid phosphorylation; regulation of small GTPase mediated signal transduction; negative regulation of neutrophil degranulation; positive regulation of phagocytosis; negative regulation of inflammatory response; small GTPase mediated signal transduction; brain development; actin cytoskeleton organization and biogenesis; neuromuscular process controlling balance; negative regulation of cell migration
Disease: Leukemia, Acute Lymphoblastic; Leukemia, Chronic Myeloid
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-BCR antibody
Pathways associated with anti-BCR antibody
Diseases associated with anti-BCR antibody
Disease Name |
Pubmed Publications |
Leukemia Antibodies |
>14946 publications with BCR and Leukemia |
Leukemia, Myeloid Antibodies |
>13462 publications with BCR and Leukemia, Myeloid |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Antibodies |
>12290 publications with BCR and Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
Leukemia, Myeloid, Acute Antibodies |
>2658 publications with BCR and Leukemia, Myeloid, Acute |
Precursor Cell Lymphoblastic Leukemia-Lymphoma Antibodies |
>1568 publications with BCR and Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Recurrence Antibodies |
>1113 publications with BCR and Recurrence |
Leukemia, T-Cell Antibodies |
>851 publications with BCR and Leukemia, T-Cell |
Lymphoma, B-Cell Antibodies |
>744 publications with BCR and Lymphoma, B-Cell |
Neoplasms, Experimental Antibodies |
>495 publications with BCR and Neoplasms, Experimental |
Bone Neoplasms Antibodies |
>338 publications with BCR and Bone Neoplasms |
Organs/Tissues associated with anti-BCR antibody
|